Literature DB >> 20837797

Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study system for evaluation of stereoscopic color fundus photographs and fluorescein angiograms: SCORE Study Report 9.

Barbara A Blodi1, Amitha Domalpally, Ingrid U Scott, Michael S Ip, Neal L Oden, Julee Elledge, Kelly Warren, Michael M Altaweel, Judy E Kim, Paul C Van Veldhuisen.   

Abstract

OBJECTIVE: To describe the procedures and reproducibility for grading stereoscopic color fundus photographs and fluorescein angiograms of participants in the SCORE Study.
METHODS: Standardized stereoscopic fundus photographs and fluorescein angiograms taken at 84 clinical centers were evaluated by graders at a central reading center. Type of retinal vein occlusion (RVO), area of retinal thickening, and area of retinal hemorrhage are evaluated from fundus photographs; area of fluorescein leakage and area of capillary nonperfusion are measured on fluorescein angiography. Temporal reproducibility consisted of annual regrading of a randomly selected dedicated subset of fundus photographs (60 subjects) and fluorescein angiograms (40 subjects) for 3 successive years. Contemporaneous reproducibility involved monthly regrading of a 5% random selection of recently evaluated fundus photographs (n = 73).
RESULTS: The intergrader agreement for RVO type and presence of retinal thickening was greater than 90% in the 3 annual regrades. The intraclass correlation (ICC) for area of retinal thickening in the 3 years ranged from 0.39 to 0.64 and for area of retinal hemorrhage, 0.87 to 0.96. The ICC for area of fluorescein leakage ranged from 0.66 to 0.75 and for capillary nonperfusion, 0.94 to 0.97. The contemporaneous reproducibility results were similar to those of temporal reproducibility for all variables except area of retinal thickening (ICC, 0.84).
CONCLUSIONS: The fundus photography and fluorescein angiography grading procedures for the SCORE Study are reproducible and can be used for multicenter longitudinal studies of RVO. A systematic temporal drift occurred in evaluating area of retinal thickening.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20837797      PMCID: PMC2965070          DOI: 10.1001/archophthalmol.2010.193

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  7 in total

1.  Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

2.  Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

3.  The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study system for evaluation of optical coherence tomograms: SCORE study report 4.

Authors:  Amitha Domalpally; Barbara A Blodi; Ingrid U Scott; Michael S Ip; Neal L Oden; Andreas K Lauer; Paul C VanVeldhuisen
Journal:  Arch Ophthalmol       Date:  2009-11

4.  Central vein occlusion study of photocoagulation. Manual of operations. Central Vein Occlusion Study Group.

Authors: 
Journal:  Online J Curr Clin Trials       Date:  1993-10-02

5.  SCORE Study report 3: study design and baseline characteristics.

Authors:  Michael S Ip; Neal L Oden; Ingrid U Scott; Paul C VanVeldhuisen; Barbara A Blodi; Maria Figueroa; Andrew Antoszyk; Michael Elman
Journal:  Ophthalmology       Date:  2009-07-19       Impact factor: 12.079

6.  Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2.

Authors:  Larry D Hubbard; Ronald P Danis; Michael W Neider; Dennis W Thayer; Hugh D Wabers; James K White; Anthony J Pugliese; Michael F Pugliese
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-17       Impact factor: 4.799

7.  SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type.

Authors:  Ingrid U Scott; Barbara A Blodi; Michael S Ip; Paul C Vanveldhuisen; Neal L Oden; Clement K Chan; Victor Gonzalez
Journal:  Ophthalmology       Date:  2009-04       Impact factor: 12.079

  7 in total
  17 in total

1.  Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10.

Authors:  Ingrid U Scott; Paul C VanVeldhuisen; Neal L Oden; Michael S Ip; Barbara A Blodi; Mary Elizabeth Hartnett; Geoff Cohen
Journal:  Ophthalmology       Date:  2011-02       Impact factor: 12.079

2.  SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.

Authors:  Clement K Chan; Michael S Ip; Paul C Vanveldhuisen; Neal L Oden; Ingrid U Scott; Michael J Tolentino; Barbara A Blodi
Journal:  Ophthalmology       Date:  2011-03-26       Impact factor: 12.079

3.  Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion.

Authors:  Raafay Sophie; Gulnar Hafiz; Adrienne W Scott; Ingrid Zimmer-Galler; Quan Dong Nguyen; Howard Ying; Diana V Do; Sharon Solomon; Akrit Sodhi; Peter Gehlbach; Elia Duh; David Baranano; Peter A Campochiaro
Journal:  Am J Ophthalmol       Date:  2013-10       Impact factor: 5.258

4.  Structural and functional changes to the retina and optic nerve following panretinal photocoagulation over a 2-year time period.

Authors:  R Filek; P Hooper; T Sheidow; J Gonder; D K Varma; L Heckler; W Hodge; S Chakrabarti; C M L Hutnik
Journal:  Eye (Lond)       Date:  2017-04-28       Impact factor: 3.775

5.  Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time.

Authors:  Paolo S Silva; Dennis M Marcus; Danni Liu; Lloyd Paul Aiello; Andrew Antoszyk; Michael Elman; Scott Friedman; Adam R Glassman; Joseph M Googe; Lee Merrill Jampol; Daniel F Martin; Michele Melia; Carin M Preston; Charles C Wykoff; Jennifer K Sun
Journal:  JAMA Ophthalmol       Date:  2022-10-01       Impact factor: 8.253

6.  Influence of diabetes and diabetes type on anatomic and visual outcomes following central rein vein occlusion.

Authors:  J G Santiago; S Walia; J K Sun; J D Cavallerano; Z A Haddad; L P Aiello; P S Silva
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

7.  [Ultra-widefield angiography for retinal vein occlusion : How large is large enough?]

Authors:  M Storch; S Bemme; M Rehak; H Hoerauf; N Feltgen
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

8.  SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials.

Authors:  Andrew Hendrick; Paul C VanVeldhuisen; Ingrid U Scott; Jacquie King; Barbara A Blodi; Michael S Ip; Rahul N Khurana; Neal L Oden
Journal:  Am J Ophthalmol       Date:  2020-08-20       Impact factor: 5.258

Review 9.  Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion.

Authors:  Dina Gewaily; Karthikeyan Muthuswamy; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2015-09-09

Review 10.  Treatments for macular oedema following central retinal vein occlusion: systematic review.

Authors:  John A Ford; Christine Clar; Noemi Lois; Samantha Barton; Sian Thomas; Rachel Court; Deepson Shyangdan; Norman Waugh
Journal:  BMJ Open       Date:  2014-02-10       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.